Report of Foreign Issuer (6-k)
February 17 2017 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of February, 2017
Commission File Number:
001-36000
XTL Biopharmaceuticals Ltd.
(Translation of registrant’s name
into English)
5 HaCharoshet St., Raanana,
4365603, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F
x
Form
40-F
¨
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085,
File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 333-194338).
On February 17, 2017, XTL Biopharmaceuticals
Ltd. announced it has entered into definitive agreements with institutional investors for the sale of securities with gross proceeds
of $2,500,000. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibit Index
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release dated February 17, 2017
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
XTL BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
|
|
|
|
Date: February 17, 2017
|
By:
|
/s/ Josh Levine
|
|
|
|
Josh Levine
|
|
|
|
Chief Executive Officer
|
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Aug 2024 to Sep 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Sep 2023 to Sep 2024